FTSE 100-listed pharmaceuticals group GlaxoSmithKline (GSK) has announced plans to sell its Lucozade and Ribena brands during its less-than-impressive first quarter results, which showed a two per cent contraction in group sales.
Some analysts have suggested that the decision to sell the brands could earn the company in the region of £1.0bn.
GSK said that the results reflected the ongoing contribution from 'key growth drivers', which were offset by anticipated 'demanding' prior year comparisons.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Pre-tax profit for the period declined from £1.86bn to £1.41bn year-on-year.
Excluding the divestments primarily of Vesicare and non-core OTC brands, sales rose 2.0% during the period.
Pharmaceuticals and Vaccines sales fell 2.0%, while Consumer Healthcare rose 1.0%.
The group reported an adjusted net cash inflow from operating activities of £1.4bn, up from £1.1bn in the first quarter of 2012.
The group reported that during the period it had delivered core earnings per share of 26.9p and a dividend of 18p.
Sir Andrew Witty, Chief Executive Officer of GlaxoSmithKline, said: "This quarter marks continued strategic delivery for GSK with sales and earnings in line with our expectations, significant pipeline progress and further growth in our returns to shareholders through a 6.0% increase in the dividend."
He said that the group is implementing a "major new change programme" designed to improve the competitiveness of its European Pharmaceuticals business and also restructure its manufacturing and research and development businesses to simplify its operating model and release resources.
"The initial phases of these programmes are progressing well and remain on track to deliver total annual savings of at least £1.0bn by 2016. In the short term, the benefits of our restructuring programmes are not only helping to offset some of the margin pressure we are seeing due to the changing shape of our business but also are supporting the investment behind our continuing preparations for the launch of the pipeline," he said.
GlaxoSmithKline's share price was up 0.57% to 1,688p at 12:58 on Wednesday.
MF
-
Paying the grandkids’ school fees could generate a shock IHT billPrivate school fees have soared as a result of the government’s VAT policy, meaning more grandparents are helping out – but what are the tax implications?
-
Number of savings deals hits record high – as interest rates slump to two-year lowSavers have more choice than ever when it comes to choosing a savings account or cash ISA. But, the interest rates on offer continue to fall. What’s next for the savings market?
